Metformine Hci 1a Pharma (Metformin Hydrochloride)

• Metformin Hydrochloride is used in the management of disorders related to impaired glucose metabolism.
• Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels.
• Impaired glucose tolerance (prediabetes): delays progression to type 2 diabetes when combined with lifestyle measures.
• Polycystic ovary syndrome (off‑label): may improve insulin resistance and restore ovulatory function.

• Metformin Hydrochloride primarily inhibits hepatic gluconeogenesis and reduces hepatic glucose output. It activates AMP‑activated protein kinase (AMPK), enhancing peripheral glucose uptake in muscle and adipose tissue while decreasing intestinal glucose absorption. These actions collectively improve insulin sensitivity and lower circulating blood glucose concentrations without directly stimulating insulin secretion.

Metformine Hci 1a Pharma may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Nausea
• Diarrhea
• Abdominal discomfort
• Metallic taste
• Loss of appetite
• Weight loss

Serious or Rare Side Effects

• Lactic acidosis
• Severe hypoglycemia (especially with concomitant insulin or sulfonylureas)
• Hepatotoxicity
• Severe skin reactions such as Stevens‑Johnson syndrome
• Anemia
• Acute renal impairment

• When prescribing Metformine Hci 1a Pharma, clinicians should consider several precautionary measures to ensure safe use.
• Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter.
• Hepatic disease: avoid use in patients with significant liver impairment.
• Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia.
• Alcohol consumption: limit intake to reduce lactic acidosis risk.
• Pregnancy and lactation: assess benefit‑risk; use only if clearly needed.
• Store below 25°C: keep in the original pack, protect from moisture.

Metformine Hci 1a Pharma can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure, temporarily discontinue metformin.
• Cimetidine: increases metformin plasma concentrations, risk of toxicity.
• Nucleoside reverse transcriptase inhibitors (e.g., didanosine): raise risk of lactic acidosis.
• Alcohol abuse: synergistic effect on lactic acidosis.
• Renal toxic drugs (e.g., aminoglycosides): exacerbate renal impairment.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Diuretics (thiazides): can increase blood glucose, requiring dose adjustment.
• Corticosteroids: may raise glucose levels, monitor control.
• ACE inhibitors/ARBs: may affect renal function, monitor creatinine.
• Oral contraceptives: may slightly increase metformin levels.